Largest health care biotech companies by total assets
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 health care biotech companies ranked by total assets, at CHF 76.3B, ahead of Gilead Sciences (CHF 49.7B) and Biogen (CHF 24.8B). Figures as of 19 Nov 2026, 15:48 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenCHF 76.3B
- Median
- CHF 2.2B
- Combined market value
- CHF 695.3B
- Countries
- 5
Market values as of .
All countries▾
Health Care▾
Biotech▾
| # | Company | Total assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | CHF 76.3B | CHF 199B | CHF 367.88 | 1.66% down | 32% up | ||
| 2 | Gilead SciencesGILD · Health Care | CHF 49.7B | CHF 172.9B | CHF 139.37 | 2.13% down | 35% up | ||
| 3 | BiogenBIIB · Health Care | CHF 24.8B | CHF 30.7B | CHF 207.55 | 2.04% down | 49% up | ||
| 4 | BioNTechBNTX · Health Care | CHF 20.6B | CHF 17.1B | CHF 69.09 | 1.54% down | 14% down | ||
| 5 | ModernaMRNA · Health Care | CHF 10.4B | CHF 66.4B | CHF 164.14 | 1.02% down | 780% up | ||
| 6 | argenxARGX · Health Care | CHF 7.3B | CHF 49.6B | CHF 788.37 | 0.61% down | 2% up | ||
| 7 | QiagenQGEN · Health Care | CHF 5.3B | CHF 8.6B | CHF 41.86 | 0.22% up | 9% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | CHF 3.9B | CHF 13.5B | CHF 133.53 | 2.71% down | 17% up | ||
| 9 | VaxcytePCVX · Health Care | CHF 2.5B | CHF 7.9B | CHF 49.70 | 0.78% up | 23% up | ||
| 10 | RepligenRGEN · Health Care | CHF 2.5B | CHF 9.5B | CHF 148.42 | 2.00% up | 12% up | ||
| 11 | ExelixisEXEL · Health Care | CHF 2.4B | CHF 13.5B | CHF 55.35 | 3.82% down | 63% up | ||
| 12 | Bio-TechneTECH · Health Care | CHF 2.2B | CHF 9.6B | CHF 61.28 | 0.04% down | 24% up | ||
| 13 | Halozyme TherapeuticsHALO · Health Care | CHF 2.1B | CHF 8.8B | CHF 77.14 | 4.45% down | 39% up | ||
| 14 | Revolution MedicinesRVMD · Health Care | CHF 2B | CHF 29.7B | CHF 137.16 | 1.84% up | 129% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | CHF 1.9B | CHF 3.3B | CHF 34.00 | 0.40% up | 18% down | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | CHF 1.5B | CHF 8.6B | CHF 100.19 | 1.85% down | 87% up | ||
| 17 | Krystal BiotechKRYS · Health Care | CHF 1.1B | CHF 7.9B | CHF 265.27 | 0.18% down | 54% up | ||
| 18 | ImmunovantIMVT · Health Care | CHF 806.5M | CHF 5.7B | CHF 27.67 | 1.03% down | 46% up | ||
| 19 | CG OncologyCGON · Health Care | CHF 667.1M | CHF 6.1B | CHF 68.69 | 1.89% up | 97% up | ||
| 20 | Twist BioscienceTWST · Health Care | CHF 540.9M | CHF 6.9B | CHF 100.61 | 2.60% up | 346% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | CHF 432.1M | CHF 3.9B | CHF 24.26 | 1.16% up | 74% up | ||
| 22 | ImmunityBioIBRX · Health Care | CHF 423M | CHF 5.8B | CHF 5.46 | 3.28% down | 232% up | ||
| 23 | Scholar Rock HoldingSRRK · Health Care | CHF 340.7M | CHF 5.1B | CHF 41.44 | 2.44% up | 26% up | ||
| 24 | Kodiak SciencesKOD · Health Care | CHF 296.2M | CHF 5.3B | CHF 81.30 | 1.37% down | 399% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8427 CHF).
Questions and answers
Which health care biotech companies rank first by total assets?
Amgen (CHF 76.3B), Gilead Sciences (CHF 49.7B) and Biogen (CHF 24.8B) are the top three of the 24 health care biotech companies ranked by total assets as of 19 Nov 2026, 15:48 UTC.
How many health care biotech companies are in this ranking?
24 are ranked by total assets.
What are these health care biotech companies worth together?
The 24 health care biotech companies ranked by total assets have a combined market value of CHF 695.3B as of 19 Nov 2026, 15:48 UTC.
What does ranking by total assets measure?
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest health care biotech companies by total assets”, data as of 19 November 2026. https://funkfolio.com/companies/category/biotech?sector=health-care&by=total-assets
Underlying data: Yahoo Finance; SEC EDGAR.